umu.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Lundberg, Lennart
Alternative names
Publications (8 of 8) Show all publications
Jonsson, P., Lindmark, L., Axelsson, J., Karlsson, L., Lundberg, L. & Stegmayr, B. (2018). Formation of Blood Foam in the Air Trap During Hemodialysis Due to Insufficient Automatic Priming of Dialyzers. Artificial Organs, 42(5), 533-539
Open this publication in new window or tab >>Formation of Blood Foam in the Air Trap During Hemodialysis Due to Insufficient Automatic Priming of Dialyzers
Show others...
2018 (English)In: Artificial Organs, ISSN 0160-564X, E-ISSN 1525-1594, Vol. 42, no 5, p. 533-539Article in journal (Refereed) Published
Abstract [en]

We were encouraged to investigate the reasons for large amounts of foam observed in bloodlines during hemodialysis (HD). Foam was visible in the venous air trap within the Artis Gambro dialysis device. Estimates of the extent of foam were graded (0no foam, 10extensive foam) by two persons that were blind to the type of dialyzer used. Thirty-seven patients were involved in the dialysis procedures. Consecutive dialyses were graded using dialyzers from Fresenius Medical Care (CorDiax dialyzers that were used for high flux HDFX80 and FX100, and for hemodiafiltrationFX1000). The extracorporeal circuit was primed automatically by dialysate using Gambro Artis software 8.15 006 (Gambro, Dasco, Medolla Italy, Baxter, Chicago, IL, USA). The priming volume recommended by the manufacturer was 1100 mL, whereas our center uses 1500 mL. Extensive amounts of blood foam were visual in the air traps. Although the manufacturer recommended extension of priming volume up to 3000 mL, this did not eliminate the foam. Microbubble measurement during HD revealed the air to derive from the dialyzers. When changing to PF210H dialyzers (Baxter) and using a priming volume of 1500 mL, the foam was significantly less (P<0.01). The extent of foam correlated with the size of the FX-dialyzer surface (P=0.002). The auto-priming program was updated to version 8.21 by the manufacturer and the extent of foam in the air trap using FX dialyzers was now reduced and there was no longer a difference between FX and PF dialyzers, although less foam was still visible in the venous air trap during several dialyses. In conclusion, this study urgently calls attention to blood foam development in the venous air trap when using Artis devices and priming software 8.15 in combination with Fresenius dialyzers. Updated auto-priming software (version 8.21) of Artis should be requested to reduce the extent of foam for the Fresenius dialyzers. Other interactions may also be present. We recommend further studies to clarify these problems. Meanwhile caution is warranted for the combined use of dialysis devices and dialyzers with incompatible automatic priming.

Keywords
dialysis, priming, foam, bubbles, air, blood
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:umu:diva-149031 (URN)10.1111/aor.13070 (DOI)000433563800012 ()29542180 (PubMedID)2-s2.0-85047846399 (Scopus ID)
Available from: 2018-06-14 Created: 2018-06-14 Last updated: 2019-05-20Bibliographically approved
Graaff, R., Arsov, S., Ramsauer, B., Koetsier, M., Sundvall, N., Engels, G. E., . . . Stegmayr, B. (2014). Skin and Plasma Autofluorescence During Hemodialysis: A Pilot Study. Artificial Organs, 38(6), 515-518
Open this publication in new window or tab >>Skin and Plasma Autofluorescence During Hemodialysis: A Pilot Study
Show others...
2014 (English)In: Artificial Organs, ISSN 0160-564X, E-ISSN 1525-1594, Vol. 38, no 6, p. 515-518Article in journal (Refereed) Published
Abstract [en]

Skin autofluorescence (AF) is related to the accumulation of advanced glycation end products (AGEs) and is one of the strongest prognostic markers of mortality in hemodialysis (HD) patients. The aim of this pilot study was to investigate whether changes in skin AF appear after a single HD session and if they might be related to changes in plasma AF. Skin and plasma AF were measured before and after HD in 35 patients on maintenance HD therapy (nine women and 26 men, median age 68 years, range 33-83). Median dialysis time was 4h (range 3-5.5). Skin AF was measured noninvasively with an AGE Reader, and plasma AF was measured before and after HD at 460nm after excitation at 370nm. The HD patients had on average a 65% higher skin AF value than age-matched healthy persons (P<0.001). Plasma AF was reduced by 14% (P<0.001), whereas skin AF was not changed after a single HD treatment. No significant influence of the reduced plasma AF on skin AF levels was found. This suggests that the measurement of skin AF can be performed during the whole dialysis period and is not directly influenced by the changes in plasma AF during HD.

Keywords
Hemodialysis, Skin autofluorescence, Plasma autofluorescence, Advanced glycation end products
National Category
Hematology
Identifiers
urn:nbn:se:umu:diva-91206 (URN)10.1111/aor.12205 (DOI)000337513600014 ()
External cooperation:
Available from: 2014-07-22 Created: 2014-07-21 Last updated: 2018-06-07Bibliographically approved
Stegmayr, B., Raumsaur, B., Arsov, S., Lundberg, L., Rakhorst, G., Sikole, A. & Graaff, R. (2011). How can we optimize hemodialysis to prevent from ages. International Journal of Artificial Organs, 34(8), 607-607
Open this publication in new window or tab >>How can we optimize hemodialysis to prevent from ages
Show others...
2011 (English)In: International Journal of Artificial Organs, ISSN 0391-3988, E-ISSN 1724-6040, Vol. 34, no 8, p. 607-607Article in journal (Other academic) Published
National Category
Biomedical Laboratory Science/Technology
Identifiers
urn:nbn:se:umu:diva-52057 (URN)10.5301/IJAO.2011.8701 (DOI)000299017900006 ()
Note
Abstracts of XXXVIII Annual ESAO & IV Biennial IFAO Congress, 9-12 October 2011, Porto, Portugal. Available from: 2012-03-09 Created: 2012-02-08 Last updated: 2018-06-08Bibliographically approved
Mahmood, D., Grubbström, M., Lundberg, L. D., Olivecrona, G., Olivecrona, T. & Stegmayr, B. G. (2010). Lipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysis. BMC Nephrology, 11, Article ID 33.
Open this publication in new window or tab >>Lipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysis
Show others...
2010 (English)In: BMC Nephrology, ISSN 1471-2369, E-ISSN 1471-2369, Vol. 11, article id 33Article in journal (Refereed) Published
Abstract [en]

Background: Low molecular weight (LMW) heparins are used for anticoagulation during hemodialysis (HD). Studies in animals have shown that LMW-heparins release lipoprotein lipase (LPL) as efficiently as unfractionated (UF) heparin, but are less able to retard hepatic uptake of the lipase. This raises a concern that the LPL system may become exhausted by LMW-heparin in patients on HD. We have explored this in the setting of clinical HD.

Methods: Twenty patients on chronic hemodialysis were switched from a primed infusion of UF-heparin to a single bolus of tinzaparin. There were long term follow up of variables for the estimation of dialysis efficacy as well as of the LPL release during dialysis and the subsequent impact on the triglycerides.

Results: The LPL activity in blood was higher on tinzaparin at 40 but lower at 180 minutes during HD. These values did not change during the 6 month study period. There were significant correlations between the LPL activities in individual patients at the beginning and end of the 6 month study period and between the activities on UF-heparin and on tinzaparin, indicating that tissue LPL was not being exhausted. Triglycerides were higher during the HD-session with tinzaparin than UF-heparin. The plasma lipid/lipoprotein levels did not change during the 6 month study period, nor during a 2-year follow up after the switch from UF-heparin to tinzaparin. Urea reduction rate and Kt/V were reduced by 4 and 7% after 6 months with tinzaparin.

Conclusion: Our data demonstrate that repeated HD with UF-heparin or tinzaparin does not exhaust the LPL-system.

Place, publisher, year, edition, pages
London: BioMed Central, 2010
National Category
Urology and Nephrology
Research subject
Physical Chemistry
Identifiers
urn:nbn:se:umu:diva-40810 (URN)10.1186/1471-2369-11-33 (DOI)000208334900001 ()21129229 (PubMedID)
Available from: 2011-03-10 Created: 2011-03-10 Last updated: 2018-06-08Bibliographically approved
Stegmayr, B., Brännström, M., Bucht, S., Dimeny, E., Ekspong, A., Granroth, B., . . . Wikdahl, A. (2006). Minimized weight gain between hemodialysis contributes to a reduced risk of death. International Journal of Artificial Organs, 29(7), 675-680
Open this publication in new window or tab >>Minimized weight gain between hemodialysis contributes to a reduced risk of death
Show others...
2006 (English)In: International Journal of Artificial Organs, ISSN 0391-3988, E-ISSN 1724-6040, Vol. 29, no 7, p. 675-680Article in journal (Refereed) Published
Keywords
Adult, Aged, Aged; 80 and over, C-Reactive Protein/analysis, Hemodiafiltration, Humans, Kidney Failure/*mortality/therapy, Middle Aged, Proportional Hazards Models, Prospective Studies, Weight Gain
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:umu:diva-16353 (URN)16874672 (PubMedID)
Available from: 2007-09-12 Created: 2007-09-12 Last updated: 2018-06-09Bibliographically approved
Stegmayr, B., Brännström, M., Bucht, S., Crougneau, V., Dimeny, E., Ekspong, A., . . . Wikdahl, A.-M. (2005). Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology and Nephrology, 39(6), 489-497
Open this publication in new window or tab >>Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study
Show others...
2005 (English)In: Scandinavian Journal of Urology and Nephrology, ISSN 0036-5599, E-ISSN 1651-2065, Vol. 39, no 6, p. 489-497Article in journal (Refereed) Published
Abstract [en]

Objective. There have been no endpoint studies with statins for patients with severe renal failure. The purpose of this prospective, open, randomized, controlled study was to investigate whether atorvastatin (10 mg/day) would alter cardiovascular endpoints and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 (creatinine clearance < 30 ml/min).

Material and methods. The study subjects comprised 143 patients who were randomized either to placebo (controls; n=73; mean age 69.5 years) or to treatment with atorvastatin (n=70; mean age 67.9 years). The patients included were either non-dialysis (n=33), haemodialysis (n=97) or peritoneal dialysis (n=13) patients. Analysis focused on the primary endpoints of all-cause mortality, non-lethal acute myocardial infarction, coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Statistical analysis for endpoint data was mainly by intention-to-treat.

Results. Primary endpoints occurred in 74% of the subjects. There was no difference in outcome between the control and atorvastatin groups. The 5-year endpoint-free survival rate from study entry was 20%. Atorvastatin was withdrawn in 20% of patients due to unacceptable side-effects. In the atorvastatin group, low-density lipoprotein (LDL) cholesterol was reduced by 35% at 1 month and then sustained. The controls showed a progressive reduction in LDL cholesterol until 36 months.

Conclusions. Although atorvastatin reduced total and LDL cholesterol effectively it was not beneficial regarding the long-term outcomes of cardiovascular endpoints or survival. In contrast to other patient groups, patients with severe chronic kidney disease, especially those on dialysis, seem to derive limited benefit from this lower dose of atorvastatin.

Keywords
Atorvastatin; cholesterol; chronic kidney disease; hemodialysis; high-density lipoprotein cholesterol; lipids; low-density lipoprotein cholesterol; peritoneal dialysis; risk factors; statins; triglyceride
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:umu:diva-16062 (URN)
Available from: 2007-08-16 Created: 2007-08-16 Last updated: 2018-06-09Bibliographically approved
Holmberg, B., Brännström, M., Bucht, B., Crougneau, V., Dimeny, E., Ekspong, A., . . . Stegmayr, B. (2005). Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology and Nephrology, 39(6), 503-510
Open this publication in new window or tab >>Safety and efficacy of atorvastatin in patients with severe renal dysfunction
Show others...
2005 (English)In: Scandinavian Journal of Urology and Nephrology, ISSN 0036-5599, E-ISSN 1651-2065, Vol. 39, no 6, p. 503-510Article in journal (Refereed) Published
Keywords
Cholesterol, dialysis, high-density lipoprotein, lipids, low-density lipoprotein, risk factors, triglycerides
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:umu:diva-16044 (URN)16303728 (PubMedID)
Available from: 2007-08-16 Created: 2007-08-16 Last updated: 2018-06-09Bibliographically approved
Lundberg, L. (1994). Blood-membrane interaction and treatment of haemodialysis patients: a study of various factors. (Doctoral dissertation). Umeå: Umeå universitet
Open this publication in new window or tab >>Blood-membrane interaction and treatment of haemodialysis patients: a study of various factors
1994 (English)Doctoral thesis, comprehensive summary (Other academic)
Place, publisher, year, edition, pages
Umeå: Umeå universitet, 1994. p. 59
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 402
Keywords
Haemodialysis, cellulose acetate, Hemophan®, cuprophan, complement activation, C3d, granulocyte elastase, ß-thromboglobulin, backdiffusion, leukocyte-removal filter, dialysate, acetate, bicarbonate, hollow- fibre dialyser, plate dialyser, transmembrane pressure
National Category
Clinical Medicine
Identifiers
urn:nbn:se:umu:diva-101310 (URN)91-7174-903-9 (ISBN)
Public defence
1994-06-06, sal B, 9 tr, Norrlands Universitetssjukhus, Umeå universitet, Umeå, 09:00
Projects
digitalisering@umu
Note

Diss. (sammanfattning) Umeå : Umeå universitet, 1994, härtill 5 uppsatser.

Available from: 2015-04-21 Created: 2015-03-26 Last updated: 2018-06-07Bibliographically approved
Organisations

Search in DiVA

Show all publications